Atlas Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Atlas Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.8K	Sell	60 -50	-45%	-$22.2K	﹤0.01%	806
2026 Q1	$49.1K	Hold	110	–	–	0.01%	648
2025 Q4	$49.9K	Buy	+110	New	+$47.4K	0.01%	618
2025 Q2	$49K	Buy	+110	New	+$50.7K	0.01%	628
2023 Q1	–	Sell	-162	Closed	-$46.8K	–	964
2022 Q4	$46.8K	Sell	162 -4	-2%	-$1.22K	0.01%	548
2022 Q3	$48.1K	Buy	166 +2	+1%	+$575	0.01%	540
2022 Q2	$46.2K	Buy	+164	New	+$43.9K	0.01%	573
2022 Q1	–	Sell	-5	Closed	-$1.1K	–	970
2021 Q4	$1.1K	Hold	5	–	–	﹤0.01%	873
2021 Q3	$906	Hold	5	–	–	﹤0.01%	896
2021 Q2	$1.01K	Buy	+5	New	+$1.05K	﹤0.01%	900

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Atlas Capital Advisors's VRTX Position: Q2 2026 in Review

Atlas Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 45% in Q2 2026, selling an estimated $22.2K and leaving 60 shares worth $29.8K. The position accounts for ﹤0.01% of the portfolio, ranked #806.

Atlas Capital Advisors first reported a position in VRTX in Q2 2021 and has held it in 10 quarters since. The position peaked at $49.9K in Q4 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Atlas Capital Advisors held 60 shares of Vertex Pharmaceuticals worth $29.8K as of Q2 2026.
Atlas Capital Advisors sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
Vertex Pharmaceuticals made up ﹤0.01% of Atlas Capital Advisors's portfolio in Q2 2026, its #806 holding.
Atlas Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
Atlas Capital Advisors's Vertex Pharmaceuticals position peaked at $49.9K in Q4 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.